ivabradine has been researched along with Left Ventricular Dysfunction in 78 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 23 (29.49) | 29.6817 |
| 2010's | 47 (60.26) | 24.3611 |
| 2020's | 8 (10.26) | 2.80 |
| Authors | Studies |
|---|---|
| Bao, Q; Gong, M; Li, G; Li, Y; Shao, S; Suo, Y; Wang, X; Yang, Q; Yuan, M; Zhang, Y | 1 |
| Ameri, P; Brunetti, ND; Canepa, M; Castagno, D; Correale, M; De Ferrari, GM; De Marzo, V; Porto, I; Tricarico, L; Zoccai, GB | 1 |
| Chang, JJ; Chen, MC; Jan, JY; Lin, MS; Lin, YS; Wang, PC; Yang, TY | 1 |
| Cui, D; Li, J; Liu, G; Liu, K; Lou, D; Lu, S; Ma, S; Pang, X; Wang, J; Wang, X; Wu, S; Xie, X; Xue, L; Yang, Z; Ye, F; Yu, H; Zhang, Y; Zhong, M | 1 |
| Gao, W; Guo, Y; Huang, M; Li, F; Liu, T; Xu, X | 1 |
| Agarwala, R; Kolapkar, V; Kumar, AS; Kumar, RVL; Mahala, BK; Mohan, JC; Panja, M; Patel, K; Ponde, CK; Sathyamurthy, I | 1 |
| Çetin, T; Çınar, T; Çinier, G; Eren, S; Hayıroğlu, Mİ; Keskin, K; Pay, L; Tekkeşin, Aİ; Tezen, O; Yumurtaş, AÇ | 1 |
| Hori, M; Imamura, T; Kinugawa, K; Nakamura, M | 1 |
| Berdeaux, A; Bizé, A; Bouhemad, B; Ghaleh, B; Hittinger, L; Jozwiak, M; Melka, J; Rienzo, M; Sambin, L; Su, JB | 1 |
| El-Gowilly, SM; El-Naggar, AE; Sharabi, FM | 1 |
| Chen, S; Hu, Z; Li, B; Wang, Z; Yu, Y | 1 |
| Chow, SL; Depre, C; Page, RL | 1 |
| Ali, N; Cubbon, RM; Kearney, MT; Patel, PA; Pinder, S; Roy, A; Witte, KK | 1 |
| Arboscello, E; Balbi, M; Bighin, C; Brunelli, C; Ghigliotti, G; Gualandi, F; Murialdo, R; Sarocchi, M; Sicbaldi, V; Spallarossa, P | 1 |
| Böhm, M; Borer, JS; Ferrari, R; Ford, I; Fox, K; Komajda, M; Robertson, M; Steg, PG; Swedberg, K; Tavazzi, L; Tendera, M | 1 |
| Chichkanov, GG; Tsorin, IB | 1 |
| Eriksson, U; Müller-Edenborn, B | 1 |
| Gähwiler, R; Ghadri, JR; Lüscher, TF; Templin, C | 1 |
| Clark, AL; Cleland, JG; Parsons, S | 1 |
| Adam, O; Böhm, M; Custodis, F; Laufs, U; Möhlenkamp, S; Reil, JC; Schirmer, SH | 1 |
| de Gregorio, C; Ferraro, G; Potenza, G | 1 |
| Bagriy, AE; Bagriy, EA; Malovichko, SI; Pricolota, AV; Pricolota, OA; Samoilova, OV; Schukina, EV | 1 |
| Karchik'ian, PO; Saĭganov, SA | 1 |
| Fichtlscherer, S; Fischer-Rasokat, U; Hamm, CW; Honold, J; Liebetrau, C; Lochmann, D; Möllmann, H; Spyridopoulos, I; Wolter, S | 1 |
| Haddad, H; Yip, AM; Zhai, AB | 1 |
| Cammarano, C; Comee, M; Donovan, JL; Malloy, MJ; Silva, M | 1 |
| Chan, PH; Huang, D; Lam, CC; Shea, PC; Siu, CW; Tse, HF; Yiu, KH | 1 |
| Ayhan, S; Dönmez, İ; Erdem, A; Erdem, FH; Ozturk, S; Yazıcı, M | 1 |
| Bakkehaug, JP; How, OJ; Kildal, AB; Myrmel, T; Naesheim, T; Torgersen Engstad, E | 1 |
| Khachatryan, A; Sargsyan, T; Sisakian, H | 1 |
| Allen, CJ; Guha, K; Hartley, A; Sharma, R | 1 |
| Ferrari, R; Ford, I; Fox, K; Steg, PG; Tendera, M | 3 |
| Kalra, PR; Sambu, N; Sharma, R | 1 |
| Ferrari, R; Ford, I; Fox, K; Robertson, M; Steg, PG; Tendera, M | 2 |
| Böhm, M; Reil, JC | 1 |
| Cosyns, B; D'hooge, J; Droogmans, S; Herijgers, P; Lahoutte, T; Van Camp, G; Van den Bergh, A; Weytjens, C | 1 |
| Delcayre, C; Messaoudi, S; Milliez, P; Nehme, J; Rodriguez, C; Samuel, JL | 1 |
| Goris, M; Henning, RH; Schoemaker, RG; Ulu, N; van Gilst, WH | 1 |
| D'Orazio, N; Riccioni, G; Vitulano, N | 1 |
| Agewall, S; Atar, D | 1 |
| Gensini, GF; Lanza, GA | 1 |
| Filipovský, J | 1 |
| Biriuchenko, MV; Kapelovich, VIu; Kupaeva, RA; Pozdniakova, NV; Sekerko, SA; Tatarchenko, IP | 1 |
| Heusch, G | 2 |
| Cannizzaro, S; Di Pasquale, P; Fasullo, S; Ganci, F; Giambanco, F; Maringhini, G; Migliore, G; Paterna, S; Pinto, V; Sarullo, FM; Torres, D; Vitale, G | 1 |
| Bruguera Cortada, J; Varela, A | 1 |
| Böhm, M; Reil, GH; Reil, JC | 1 |
| Berdeaux, A; Bruneval, P; Chetboul, V; Couvreur, N; Ghaleh, B; Gouni, V; Mandet, C; Pons, S; Pouchelon, JL; Tissier, R | 1 |
| Calò, L; Lioy, E; Martino, A; Sette, A | 1 |
| Bugatti, S; Dei Cas, L; Lombardi, C; Metra, M; Zacà, V | 1 |
| Bohora, S; Lokhandwala, Y; Parekh, P; Vasavda, A | 1 |
| Abuladze, GV; Chachua, TB; Dundua, GI; Kvirkveliia, AA; Nebieridze, MI | 1 |
| Asselin, C; Bouly, M; Brand, G; Busseuil, D; Des Rosiers, C; Gillis, MA; Latour, JG; Leung, TK; Mecteau, M; Rhéaume, E; Roméo, P; Shi, Y; Tardif, JC; Thorin, E | 1 |
| Ferrari, R; Ford, I; Fox, K; Robertson, M; Steg, PG; Talajic, M; Tardif, JC; Tendera, M | 1 |
| Riccioni, G | 1 |
| Fruhwald, F; Pieske, B | 1 |
| Böhm, M; Borer, JS; Ford, I; Komajda, M; O'Meara, E; Swedberg, K; Tardif, JC; Tavazzi, L | 1 |
| Clark, AL; Cleland, JG; Cullington, D; Goode, KM | 1 |
| Albajrami, O; Bellumkonda, L; Jacoby, D | 1 |
| Brakenhielm, E; Debunne, M; Fang, Y; Henry, JP; Lallemand, F; Mulder, P; Richard, V; Thuillez, C; Vercauteren, M | 1 |
| Francis, GS; Sarraf, M | 2 |
| Castagno, D; Claggett, B; McMurray, J; Petrie, MC | 1 |
| Becher, PM; Lindner, D; Miteva, K; Savvatis, K; Schmack, B; Schultheiss, HP; Tschöpe, C; Van Linthout, S; Westermann, D; Zietsch, C | 1 |
| Chilton, RJ; Lindsey, ML; Ma, Y | 1 |
| Böhm, M; Borer, J; Ford, I; Komajda, M; Robertson, M; Swedberg, K; Tavazzi, L | 1 |
| Böhm, M; Custodis, F; Fries, P; Fröhlig, G; Gräber, S; Granzier, HL; Hohl, M; Kazakov, A; Kratz, MT; Lenski, M; Müller, A; Neuberger, HR; Reil, GH; Reil, JC; Steendijk, P | 1 |
| Cowie, MR | 1 |
| Cho, KI; Han, J; Kim, BH; Kim, IJ; Kim, JY; Kim, N; Kim, SM | 1 |
| Perry, CM | 1 |
| Jung, W; Lauck, G; Manz, M; Omran, H; Reuter, M | 1 |
| Borer, JS | 1 |
| Swedberg, K | 1 |
| Agnesina, L; Bertoletti, A; Campana, C; De Ferrari, GM; Lettino, M; Mazzuero, A; Schwartz, PJ; Tavazzi, L | 1 |
19 review(s) available for ivabradine and Left Ventricular Dysfunction
| Article | Year |
|---|---|
Efficacy of new medical therapies in patients with heart failure, reduced ejection fraction, and chronic kidney disease already receiving neurohormonal inhibitors: a network meta-analysis.
Topics: Clinical Trials, Phase III as Topic; Heart Failure, Systolic; Humans; Ivabradine; Network Meta-Analysis; Randomized Controlled Trials as Topic; Renal Insufficiency, Chronic; Stroke Volume; Ventricular Dysfunction, Left | 2022 |
Role of ivabradine and heart rate lowering in chronic heart failure: guideline update.
Topics: Adrenergic beta-Antagonists; Benzazepines; Cardiovascular Agents; Chronic Disease; Heart Failure; Heart Failure, Systolic; Heart Rate; Hospitalization; Humans; Ivabradine; Treatment Outcome; Ventricular Dysfunction, Left | 2018 |
Effects of Ivabradine on Hemodynamic and Functional Parameters in Left Ventricular Systolic Dysfunction: a Systematic Review and Meta-analysis.
Topics: Blood Pressure; Cardiovascular Agents; Exercise Tolerance; Hemodynamics; Humans; Ivabradine; Stroke Volume; Treatment Outcome; Ventricular Dysfunction, Left | 2018 |
Effect of ivabradine in patients with left-ventricular systolic dysfunction: a pooled analysis of individual patient data from the BEAUTIFUL and SHIFT trials.
Topics: Adrenergic beta-Antagonists; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Benzazepines; Cardiotonic Agents; Coronary Artery Disease; Female; Heart Failure; Heart Rate; Hospitalization; Humans; Ivabradine; Kaplan-Meier Estimate; Male; Middle Aged; Myocardial Infarction; Randomized Controlled Trials as Topic; Treatment Outcome; Ventricular Dysfunction, Left | 2013 |
[Heart rate reduction due to selective specific inhibition of the If current opens new possibilities in treatment of basic cardiovascular diseases].
Topics: Adrenergic beta-Antagonists; Animals; Atherosclerosis; Benzazepines; Cardiotonic Agents; Heart; Heart Failure; Heart Rate; Humans; Ivabradine; Myocardial Ischemia; Stroke Volume; Ventricular Dysfunction, Left | 2013 |
[Heart failure - up to date].
Topics: Adrenergic beta-Antagonists; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Benzazepines; Cardiotonic Agents; Digoxin; Diuretics; Drug Therapy, Combination; Evidence-Based Medicine; Heart Failure; Hemodynamics; Humans; Ivabradine; Mineralocorticoid Receptor Antagonists; Patient Readmission; Quality of Life; Survival Rate; Ventricular Dysfunction, Left | 2013 |
[Heart rate: clinical variable and risk marker].
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Benzazepines; Cardiomyopathy, Dilated; Cardiovascular Diseases; Dose-Response Relationship, Drug; Drug Therapy, Combination; Heart Rate; Humans; Ivabradine; Male; Mineralocorticoid Receptor Antagonists; Reference Values; Risk Factors; Survival Rate; Ventricular Dysfunction, Left | 2014 |
Heart rate and heart failure.
Topics: Benzazepines; Cardiovascular Agents; Cyclic Nucleotide-Gated Cation Channels; Heart Failure; Heart Rate; Humans; Ivabradine; Outcome Assessment, Health Care; Ventricular Dysfunction, Left | 2016 |
Meta-analysis of Ivabradine in Patients With Stable Coronary Artery Disease With and Without Left Ventricular Dysfunction.
Topics: Adrenergic beta-Antagonists; Benzazepines; Coronary Artery Disease; Heart Failure; Heart Rate; Hospitalization; Humans; Ivabradine; Randomized Controlled Trials as Topic; Ventricular Dysfunction, Left | 2016 |
Ivabradine: A Current Overview.
Topics: Animals; Benzazepines; Cardiovascular Agents; Heart Failure; Heart Rate; Humans; Ivabradine; Myocardial Ischemia; Ventricular Dysfunction, Left | 2016 |
Ivabradine: beyond heart rate control.
Topics: Adrenergic beta-Antagonists; Angina Pectoris; Benzazepines; Calcium Channel Blockers; Cardiovascular Agents; Coronary Artery Disease; Heart Failure; Heart Rate; Heart Transplantation; Humans; Ivabradine; Nitrates; Randomized Controlled Trials as Topic; Ventricular Dysfunction, Left | 2009 |
Role of heart rate in cardiovascular diseases: how the results of the BEAUTIFUL study change clinical practice.
Topics: Aged; Benzazepines; Cardiovascular Diseases; Coronary Artery Disease; Female; Heart Rate; Humans; Ivabradine; Male; Middle Aged; Randomized Controlled Trials as Topic; Ventricular Dysfunction, Left | 2009 |
Heart rate reduction by I(f)-channel inhibition and its potential role in heart failure with reduced and preserved ejection fraction.
Topics: Benzazepines; Cardiotonic Agents; Heart Failure; Heart Rate; Hemodynamics; Humans; Ivabradine; Stroke Volume; Treatment Outcome; Ventricular Dysfunction, Left; Ventricular Function, Left | 2009 |
[Heart rate: a risk factor or an epiphenomenon?].
Topics: Acute Coronary Syndrome; Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Benzazepines; Calcium Channel Blockers; Cohort Studies; Cyclic Nucleotide-Gated Cation Channels; Female; Follow-Up Studies; Heart Failure; Heart Rate; Hospitalization; Humans; Hypertension; Ivabradine; Male; Middle Aged; Multivariate Analysis; Myocardial Ischemia; Prognosis; Randomized Controlled Trials as Topic; Risk Factors; Stereoisomerism; Tachycardia; Time Factors; Ventricular Dysfunction, Left | 2010 |
Heart rate and heart failure. Not a simple relationship.
Topics: Animals; Benzazepines; Cardiac Pacing, Artificial; Coronary Artery Disease; Disease Models, Animal; Heart Failure; Heart Rate; Humans; Ivabradine; Models, Cardiovascular; Multicenter Studies as Topic; Myocardial Ischemia; Myocardium; Randomized Controlled Trials as Topic; Stress, Mechanical; Tachycardia; Tachycardia, Supraventricular; Treatment Outcome; Ventricular Dysfunction, Left; Vertebrates | 2011 |
Ivabradine: recent and potential applications in clinical practice.
Topics: Angina Pectoris; Animals; Benzazepines; Cardiovascular Agents; Cardiovascular Diseases; Coronary Artery Disease; Female; Heart Rate; Humans; Ivabradine; Male; Risk Factors; Ventricular Dysfunction, Left | 2011 |
β-blockers in stage B: a precursor of heart failure.
Topics: Adrenergic beta-Antagonists; Animals; Benzazepines; Bisoprolol; Carbazoles; Cardiovascular System; Carvedilol; Disease Progression; Heart Failure; Heart Ventricles; Humans; Ivabradine; Propanolamines; Sympathetic Nervous System; Ventricular Dysfunction, Left | 2012 |
Ivabradine: in adults with chronic heart failure with reduced left ventricular ejection fraction.
Topics: Adult; Animals; Benzazepines; Cardiotonic Agents; Cyclic Nucleotide-Gated Cation Channels; Evidence-Based Medicine; Heart Failure; Heart Rate; Humans; Ivabradine; Membrane Transport Modulators; Stroke Volume; Ventricular Dysfunction, Left | 2012 |
Therapeutic effects of I(f) blockade: evidence and perspective.
Topics: Angina Pectoris; Animals; Benzazepines; Heart Rate; Humans; Ion Channels; Ivabradine; Myocardial Ischemia; Randomized Controlled Trials as Topic; Ventricular Dysfunction, Left | 2006 |
16 trial(s) available for ivabradine and Left Ventricular Dysfunction
| Article | Year |
|---|---|
Sustained-Release Ivabradine Hemisulfate in Patients With Systolic Heart Failure.
Topics: Benzazepines; Cardiovascular Agents; Delayed-Action Preparations; Double-Blind Method; Heart Failure; Heart Failure, Systolic; Heart Rate; Humans; Ivabradine; Stroke Volume; Treatment Outcome; Ventricular Dysfunction, Left; Ventricular Function, Left | 2022 |
β-Blockers and ivabradine differentially affect cardiopulmonary function and left ventricular filling index.
Topics: Adrenergic beta-Antagonists; Aged; Anti-Arrhythmia Agents; Benzazepines; Biomarkers; Coronary Artery Disease; Drug Substitution; Dyspnea; Exercise Test; Exercise Tolerance; Female; Heart Rate; Humans; Ivabradine; Male; Middle Aged; Natriuretic Peptide, Brain; Peptide Fragments; Pilot Projects; Stroke Volume; Time Factors; Treatment Outcome; Ventricular Dysfunction, Left; Ventricular Function, Left | 2016 |
Effect of selective heart rate reduction through sinus node I
Topics: Aged; Benzazepines; Cardiovascular Agents; Chronic Disease; Cyclic Nucleotide-Gated Cation Channels; Echocardiography, Doppler, Pulsed; Female; Heart Failure; Heart Rate; Humans; Ivabradine; Male; Middle Aged; Pulse Wave Analysis; Severity of Illness Index; Sinoatrial Node; Treatment Outcome; Ventricular Dysfunction, Left | 2016 |
The BEAUTIFUL study: randomized trial of ivabradine in patients with stable coronary artery disease and left ventricular systolic dysfunction - baseline characteristics of the study population.
Topics: Aged; Benzazepines; Cardiovascular Agents; Coronary Artery Disease; Diabetes Complications; Double-Blind Method; Drug Therapy, Combination; Female; Heart Failure; Humans; Ivabradine; Male; Metabolic Syndrome; Middle Aged; Myocardial Infarction; Ventricular Dysfunction, Left | 2008 |
Heart rate as a prognostic risk factor in patients with coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a subgroup analysis of a randomised controlled trial.
Topics: Aged; Benzazepines; Cardiovascular Diseases; Coronary Disease; Female; Heart Rate; Humans; Ivabradine; Male; Middle Aged; Prognosis; Proportional Hazards Models; Risk Factors; Tachycardia; Ventricular Dysfunction, Left | 2008 |
Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial.
Topics: Aged; Benzazepines; Coronary Disease; Double-Blind Method; Female; Follow-Up Studies; Heart Rate; Hospital Mortality; Humans; Ivabradine; Kaplan-Meier Estimate; Male; Middle Aged; Ventricular Dysfunction, Left | 2008 |
[The BEAUTIFUL study].
Topics: Benzazepines; Coronary Disease; Double-Blind Method; Humans; Ivabradine; Ventricular Dysfunction, Left | 2009 |
[Ivabradine in patients with stable ischemic heart disease and left ventricular systolic dysfunction: the results of the BEAUTIFUL study].
Topics: Benzazepines; Cardiotonic Agents; Double-Blind Method; Female; Heart Rate; Humans; Ivabradine; Male; Middle Aged; Myocardial Ischemia; Ventricular Dysfunction, Left | 2009 |
[Clinical efficacy of ivabradin and nebivolol addition in combined treatment of ischemic heart disease patients with left ventricular dysfunction].
Topics: Benzazepines; Benzopyrans; Dose-Response Relationship, Drug; Drug Therapy, Combination; Echocardiography, Doppler, Color; Electrocardiography; Ethanolamines; Follow-Up Studies; Humans; Ivabradine; Middle Aged; Myocardial Contraction; Myocardial Ischemia; Nebivolol; Platelet Aggregation Inhibitors; Stereoisomerism; Treatment Outcome; Vasodilator Agents; Ventricular Dysfunction, Left | 2008 |
Relationship between ivabradine treatment and cardiovascular outcomes in patients with stable coronary artery disease and left ventricular systolic dysfunction with limiting angina: a subgroup analysis of the randomized, controlled BEAUTIFUL trial.
Topics: Adult; Angina Pectoris; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Benzazepines; Coronary Artery Disease; Death, Sudden, Cardiac; Double-Blind Method; Female; Hospitalization; Humans; Ivabradine; Kaplan-Meier Estimate; Male; Middle Aged; Myocardial Infarction; Ventricular Dysfunction, Left; Young Adult | 2009 |
Comparison of ivabradine versus metoprolol in early phases of reperfused anterior myocardial infarction with impaired left ventricular function: preliminary findings.
Topics: Aged; Benzazepines; Double-Blind Method; Female; Follow-Up Studies; Humans; Ivabradine; Male; Metoprolol; Middle Aged; Myocardial Infarction; Myocardial Reperfusion Injury; Pilot Projects; Time Factors; Ventricular Dysfunction, Left | 2009 |
Safety of ivabradine in patients with coronary artery disease and left ventricular systolic dysfunction (from the BEAUTIFUL Holter Substudy).
Topics: Adrenergic beta-Antagonists; Aged; Benzazepines; Coronary Artery Disease; Double-Blind Method; Drug Therapy, Combination; Electrocardiography, Ambulatory; Female; Heart Rate; Humans; Ivabradine; Male; Middle Aged; Placebos; Systole; Treatment Outcome; Ventricular Dysfunction, Left | 2011 |
Effects of selective heart rate reduction with ivabradine on left ventricular remodelling and function: results from the SHIFT echocardiography substudy.
Topics: Aged; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Benzazepines; Double-Blind Method; Echocardiography; Female; Heart Failure; Humans; Ivabradine; Male; Middle Aged; Stroke Volume; Ventricular Dysfunction, Left; Ventricular Remodeling | 2011 |
Effects on outcomes of heart rate reduction by ivabradine in patients with congestive heart failure: is there an influence of beta-blocker dose?: findings from the SHIFT (Systolic Heart failure treatment with the I(f) inhibitor ivabradine Trial) study.
Topics: Adrenergic beta-Antagonists; Benzazepines; Cyclic Nucleotide-Gated Cation Channels; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Electrocardiography; Female; Follow-Up Studies; Global Health; Heart Failure, Systolic; Heart Rate; Humans; Ivabradine; Male; Middle Aged; Prospective Studies; Sinoatrial Node; Survival Rate; Treatment Outcome; Ventricular Dysfunction, Left | 2012 |
A single intravenous dose of ivabradine, a novel I(f) inhibitor, lowers heart rate but does not depress left ventricular function in patients with left ventricular dysfunction.
Topics: Adult; Aged; Benzazepines; Cardiomyopathy, Dilated; Coronary Disease; Echocardiography, Doppler; Female; Follow-Up Studies; Heart Function Tests; Heart Rate; Hemodynamics; Humans; Injections, Intravenous; Ivabradine; Male; Middle Aged; Reference Values; Risk Assessment; Severity of Illness Index; Single-Blind Method; Stroke Volume; Treatment Outcome; Ventricular Dysfunction, Left; Ventricular Function, Left | 2003 |
Favourable effects of heart rate reduction with intravenous administration of ivabradine in patients with advanced heart failure.
Topics: Adult; Benzazepines; Drug Administration Schedule; Female; Heart Failure; Heart Rate; Humans; Infusions, Intravenous; Ivabradine; Male; Middle Aged; Pilot Projects; Stroke Volume; Treatment Outcome; Ventricular Dysfunction, Left | 2008 |
43 other study(ies) available for ivabradine and Left Ventricular Dysfunction
| Article | Year |
|---|---|
Ivabradine Ameliorates Cardiac Function in Heart Failure with Preserved and Reduced Ejection Fraction via Upregulation of miR-133a.
Topics: Animals; Animals, Newborn; Cardiotonic Agents; Cells, Cultured; Diastole; Disease Models, Animal; Fibroblasts; Heart Failure; Heart Ventricles; Ivabradine; Male; Mice; Mice, Inbred C57BL; MicroRNAs; Rats; Rats, Sprague-Dawley; Signal Transduction; Stroke Volume; Systole; Transfection; Treatment Outcome; Up-Regulation; Ventricular Dysfunction, Left | 2021 |
Ivabradine in heart failure patients with reduced ejection fraction and history of paroxysmal atrial fibrillation.
Topics: Atrial Fibrillation; Cohort Studies; Heart Failure; Humans; Ivabradine; Stroke Volume; Ventricular Dysfunction, Left | 2022 |
Ivabradine monotherapy in pediatric patients with focal atrial tachycardia: a single-center study.
Topics: Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Cardiomyopathies; Child; Female; Humans; Ivabradine; Stroke Volume; Tachycardia; Treatment Outcome; Ventricular Dysfunction, Left; Ventricular Function, Left | 2023 |
Expert Consensus on Ivabradine-based Therapy for Heart Rate Management in Chronic Coronary Syndrome and Heart Failure with Reduced Ejection Fraction in India.
Topics: Adrenergic beta-Antagonists; Consensus; Heart Failure; Heart Rate; Humans; Ivabradine; Stroke Volume; Syndrome; Ventricular Dysfunction, Left | 2023 |
Effect of ivabradine on ventricular arrhythmias in heart failure patients with reduced ejection fraction.
Topics: Arrhythmias, Cardiac; Heart Failure; Humans; Ivabradine; Retrospective Studies; Stroke Volume; Tachycardia, Ventricular; Ventricular Dysfunction, Left | 2023 |
Implication of Ivabradine in Up-titrating Beta-blocker in a Patient with Advanced Heart Failure.
Topics: Adrenergic beta-Antagonists; Benzazepines; Heart Failure; Heart Rate; Humans; Ivabradine; Ventricular Dysfunction, Left | 2021 |
Ivabradine improves left ventricular twist and untwist during chronic hypertension.
Topics: Animals; Benzazepines; Cardiovascular Agents; Chronic Disease; Female; Hypertension; Hypertrophy, Left Ventricular; Ivabradine; Swine; Ventricular Dysfunction, Left | 2018 |
Possible Ameliorative Effect of Ivabradine on the Autonomic and Left Ventricular Dysfunction Induced by Doxorubicin in Male Rats.
Topics: Animals; Arterial Pressure; Autonomic Nervous System; Autonomic Nervous System Diseases; Baroreflex; Cardiotoxicity; Cardiovascular Agents; Cardiovascular System; Disease Models, Animal; Doxorubicin; Heart Failure; Heart Rate; Ivabradine; Male; Rats, Wistar; Ventricular Dysfunction, Left; Ventricular Function, Left; Ventricular Pressure | 2018 |
Ivabradine improved left ventricular function and pressure overload-induced cardiomyocyte apoptosis in a transverse aortic constriction mouse model.
Topics: Animals; Aortic Diseases; Apoptosis; Cardiovascular Agents; Constriction, Pathologic; Disease Models, Animal; Hypertrophy, Left Ventricular; Ivabradine; Male; Mice; Mice, Inbred C57BL; Myocytes, Cardiac; Pressure; Ventricular Dysfunction, Left | 2019 |
Ivabradine in Cancer Treatment-Related Left Ventricular Dysfunction.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Anthracyclines; Cardiovascular Agents; Dose-Response Relationship, Drug; Fatigue; Female; Heart Rate; Humans; Ivabradine; Male; Middle Aged; Neoplasms; Retrospective Studies; Trastuzumab; Ventricular Dysfunction, Left | 2018 |
[A heart without overspeed trip unit].
Topics: Adult; Algorithms; Benzazepines; Bisoprolol; Diagnosis, Differential; Drug Therapy, Combination; Echocardiography; Electrocardiography; Electrocardiography, Ambulatory; Exercise Test; Firefighters; Humans; Ivabradine; Male; Metoprolol; Oxygen; Physical Examination; Physical Fitness; Signal Processing, Computer-Assisted; Tachycardia, Sinus; Ventricular Dysfunction, Left | 2014 |
The remarkable effect of ivabradine in two adolescents with dilated cardiomyopathy.
Topics: Adolescent; Benzazepines; Cardiomyopathy, Dilated; Cardiovascular Agents; Humans; Ivabradine; Male; Treatment Outcome; Ventricular Dysfunction, Left | 2014 |
Effectiveness of the combination therapy with lisinopril, ivabradine and multivitamin supplementation in anthracycline-induced severe cardiotoxicity.
Topics: Anthracyclines; Antibiotics, Antineoplastic; Benzazepines; Cardiotoxicity; Dietary Supplements; Drug Therapy, Combination; Female; Humans; Ivabradine; Lisinopril; Middle Aged; Treatment Outcome; Ventricular Dysfunction, Left; Vitamins | 2014 |
Addition of ivabradine to β-blocker improves exercise capacity in systolic heart failure patients in a prospective, open-label study.
Topics: Adrenergic beta-Antagonists; Aged; Benzazepines; Carbazoles; Cardiovascular Agents; Carvedilol; Drug Therapy, Combination; Exercise; Exercise Tolerance; Female; Heart Failure, Systolic; Heart Rate; Humans; Ivabradine; Male; Middle Aged; Propanolamines; Prospective Studies; Risk Factors; Ventricular Dysfunction, Left | 2015 |
[Correction of sinus rate by inhibitors of If-channels in patients with acute decompensated heart failure].
Topics: Acute Disease; Aged; Benzazepines; Cardiovascular Agents; Dose-Response Relationship, Drug; Drug Monitoring; Echocardiography; Exercise Test; Female; Heart Failure, Systolic; Heart Rate; Humans; Ivabradine; Male; Middle Aged; Statistics as Topic; Treatment Outcome; Ventricular Dysfunction, Left; Ventricular Function, Left | 2014 |
Ivabradine in Severe Aortic Stenosis with Poor Left Ventricular Ejection Fraction.
Topics: Aged, 80 and over; Aortic Valve Stenosis; Benzazepines; Cardiac Catheterization; Cardiovascular Agents; Electrocardiography; Heart Failure, Systolic; Heart Rate; Heart Valve Prosthesis Implantation; Humans; Ivabradine; Male; Recovery of Function; Severity of Illness Index; Stroke Volume; Treatment Outcome; Ventricular Dysfunction, Left; Ventricular Function, Left | 2015 |
The effects of ivabradine on left atrial electromechanical function in patients with systolic heart failure.
Topics: Benzazepines; Cardiovascular Agents; Female; Heart Failure; Heart Rate; Humans; Ivabradine; Male; Middle Aged; Stroke Volume; Treatment Outcome; Ventricular Dysfunction, Left | 2016 |
Reversing dobutamine-induced tachycardia using ivabradine increases stroke volume with neutral effect on cardiac energetics in left ventricular post-ischaemia dysfunction.
Topics: Animals; Benzazepines; Cardiac Output; Cardiotonic Agents; Coronary Circulation; Dobutamine; Energy Metabolism; Heart; Heart Rate; In Vitro Techniques; Ivabradine; Male; Mice; Myocardial Ischemia; Myocardium; Oxygen Consumption; Stroke Volume; Swine; Tachycardia; Ventricular Dysfunction, Left | 2016 |
Multiple coronary to left ventricular fistulae.
Topics: Adult; Arterio-Arterial Fistula; Benzazepines; Coronary Vessel Anomalies; Coronary Vessels; Female; Heart Ventricles; Humans; Ivabradine; Ultrasonography; Ventricular Dysfunction, Left | 2009 |
BEAUTIFUL results--the slower, the better?
Topics: Adrenergic beta-Antagonists; Benzazepines; Coronary Disease; Heart Rate; Humans; Ivabradine; Randomized Controlled Trials as Topic; Tachycardia; Ventricular Dysfunction, Left | 2008 |
Influence of heart rate reduction on Doppler myocardial imaging parameters in a small animal model.
Topics: Animals; Benzazepines; Echocardiography; Echocardiography, Doppler; Heart Rate; Hemodynamics; Ivabradine; Male; Models, Animal; Myocardial Contraction; Rats; Rats, Wistar; Ventricular Dysfunction, Left | 2009 |
Beneficial effects of delayed ivabradine treatment on cardiac anatomical and electrical remodeling in rat severe chronic heart failure.
Topics: Animals; Anti-Arrhythmia Agents; Benzazepines; Collagen; Disease Models, Animal; Drug Administration Schedule; Echocardiography, Doppler; Electrocardiography, Ambulatory; Fibrosis; Heart Failure; Heart Rate; Ivabradine; Male; Myocardial Infarction; Myocardium; Peptidyl-Dipeptidase A; Rats; Rats, Wistar; Receptor, Angiotensin, Type 1; Renin-Angiotensin System; RNA, Messenger; Severity of Illness Index; Stroke Volume; Telemetry; Ventricular Dysfunction, Left; Ventricular Function, Left; Ventricular Pressure; Ventricular Remodeling | 2009 |
Effects of ivabradine and metoprolol on cardiac angiogenesis and endothelial dysfunction in rats with heart failure.
Topics: Animals; Benzazepines; Heart Failure; Heart Rate; Ivabradine; Male; Metoprolol; Myocardial Infarction; Rats; Rats, Wistar; Ventricular Dysfunction, Left | 2009 |
Interpreting clinical trials: the 'beautiful' case.
Topics: Benzazepines; Cardiovascular Agents; Coronary Artery Disease; Endpoint Determination; Heart Rate; Humans; Ivabradine; Randomized Controlled Trials as Topic; Ventricular Dysfunction, Left | 2009 |
A BEAUTIFUL lesson--ivabradine protects from ischaemia, but not from heart failure: through heart rate reduction or more?
Topics: Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Benzazepines; Coronary Artery Disease; Heart Failure; Humans; Ivabradine; Myocardial Ischemia; Retrospective Studies; Ventricular Dysfunction, Left | 2009 |
Chronic heart rate reduction with ivabradine improves systolic function of the reperfused heart through a dual mechanism involving a direct mechanical effect and a long-term increase in FKBP12/12.6 expression.
Topics: Animals; Anti-Arrhythmia Agents; Benzazepines; Blotting, Western; Calcium-Binding Proteins; Coronary Occlusion; Heart Rate; Ivabradine; Myocardial Infarction; Myocardial Reperfusion; Rabbits; Stroke Volume; Tacrolimus Binding Protein 1A; Ventricular Dysfunction, Left | 2010 |
Efficacy of ivabradine in a case of inappropriate sinus tachycardia and ventricular dysfunction.
Topics: Anti-Arrhythmia Agents; Benzazepines; Electrocardiography; Heart Rate; Humans; Ivabradine; Male; Middle Aged; Quality of Life; Stroke Volume; Tachycardia, Sinus; Time Factors; Treatment Outcome; Ventricular Dysfunction, Left; Ventricular Function, Left | 2010 |
Reversal of tachycardiomyopathy due to left atrial tachycardia by ivabradine.
Topics: Adolescent; Anti-Arrhythmia Agents; Benzazepines; Cardiomyopathies; Catheter Ablation; Electrocardiography; Electrophysiologic Techniques, Cardiac; Female; Heart Rate; Humans; Ivabradine; Stroke Volume; Tachycardia, Supraventricular; Treatment Outcome; Ventricular Dysfunction, Left; Ventricular Function, Left | 2011 |
[Clinical-hemodynamic and anti-ischemic effects ivabradine and nebivolol ischemic heart disease with left ventricular dysfunction].
Topics: Adrenergic beta-1 Receptor Antagonists; Benzazepines; Benzopyrans; Electrocardiography; Ethanolamines; Female; Hemodynamics; Humans; Ivabradine; Male; Middle Aged; Myocardial Ischemia; Nebivolol; Treatment Outcome; Ventricular Dysfunction, Left | 2010 |
Heart rate reduction by ivabradine reduces diastolic dysfunction and cardiac fibrosis.
Topics: Aldosterone; Angiotensin II; Animals; Benzazepines; Cyclic Nucleotide-Gated Cation Channels; Diastole; Echocardiography, Doppler, Pulsed; Fibrosis; Heart Atria; Heart Rate; Heart Ventricles; Hemodynamics; Hypercholesterolemia; Ivabradine; Oxidative Stress; Rabbits; Sinoatrial Node; Ventricular Dysfunction, Left | 2010 |
Left ventricular remodelling in systolic heart failure using ivabradine. Slower is smaller is better?
Topics: Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Benzazepines; Female; Heart Failure; Humans; Ivabradine; Male; Ventricular Dysfunction, Left; Ventricular Remodeling | 2011 |
Limited role for ivabradine in the treatment of chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Arrhythmias, Cardiac; Benzazepines; Cardiotonic Agents; Chronic Disease; Female; Heart Failure; Humans; Ivabradine; Male; Middle Aged; Patient Selection; Stroke Volume; Ventricular Dysfunction, Left | 2011 |
Natural history of end-stage LV dysfunction: has it improved from the classic Franciosa and Cohn Graph?
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Benzazepines; Cardiac Resynchronization Therapy; Defibrillators, Implantable; Heart Failure; Heart-Assist Devices; Humans; Hydralazine; Ivabradine; Mineralocorticoid Receptor Antagonists; Nitrates; Renin-Angiotensin System; Risk Factors; Survival Analysis; Sympathetic Nervous System; Treatment Outcome; Ventricular Dysfunction, Left; Ventricular Remodeling | 2011 |
Heart rate reduction induced by the if current inhibitor ivabradine improves diastolic function and attenuates cardiac tissue hypoxia.
Topics: Animals; Benzazepines; Cell Hypoxia; Cell Proliferation; Diastole; Disease Models, Animal; Heart Failure; Heart Rate; Hypoxia-Inducible Factor 1, alpha Subunit; Ivabradine; Male; Myocardial Infarction; Nitric Oxide; Rats; Rats, Wistar; Time Factors; Vasodilation; Ventricular Dysfunction, Left; Ventricular Function, Left | 2012 |
Should we SHIFT our thinking about digoxin? Observations on ivabradine and heart rate reduction in heart failure.
Topics: Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Benzazepines; Digoxin; Female; Heart Failure; Humans; Ivabradine; Kaplan-Meier Estimate; Male; Middle Aged; Randomized Controlled Trials as Topic; Retrospective Studies; Stroke Volume; Treatment Outcome; Ventricular Dysfunction, Left | 2012 |
Role of heart rate reduction in the prevention of experimental heart failure: comparison between If-channel blockade and β-receptor blockade.
Topics: Adrenergic beta-1 Receptor Antagonists; Angiotensin II; Animals; Apoptosis; Benzazepines; Cyclic Nucleotide-Gated Cation Channels; Cytokines; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Administration Schedule; Heart Failure; Heart Rate; Immunohistochemistry; In Situ Nick-End Labeling; Ivabradine; Male; Metoprolol; Mice; Mice, Inbred C57BL; Multivariate Analysis; Random Allocation; Sensitivity and Specificity; Statistics, Nonparametric; Tachycardia; Treatment Outcome; Ventricular Dysfunction, Left; Ventricular Remodeling | 2012 |
Heart rate reduction: an old and novel candidate heart failure therapy.
Topics: Animals; Benzazepines; Heart Failure; Ivabradine; Male; Metoprolol; Tachycardia; Ventricular Dysfunction, Left | 2012 |
It is all about heart rate. Or is it?
Topics: Adrenergic beta-Antagonists; Benzazepines; Electrocardiography; Female; Heart Failure, Systolic; Heart Rate; Humans; Ivabradine; Male; Sinoatrial Node; Ventricular Dysfunction, Left | 2012 |
Heart rate reduction by If-inhibition improves vascular stiffness and left ventricular systolic and diastolic function in a mouse model of heart failure with preserved ejection fraction.
Topics: Animals; Anti-Arrhythmia Agents; Aorta; Benzazepines; Blood Glucose; Collagen; Diastole; Heart Failure; Heart Rate; Hemodynamics; Insulin; Ivabradine; Magnetic Resonance Angiography; Male; Mice; Mice, Inbred C57BL; Protein Kinases; RNA, Messenger; Stroke Volume; Systole; Vascular Stiffness; Ventricular Dysfunction, Left | 2013 |
Recent developments in the management of heart failure.
Topics: Algorithms; Benzazepines; Cyclic Nucleotide-Gated Cation Channels; Eplerenone; Heart Failure; Humans; Ivabradine; Mineralocorticoid Receptor Antagonists; Natriuretic Peptide, Brain; Patient Care Team; Peptide Fragments; Spironolactone; Ventricular Dysfunction, Left | 2012 |
Heart rate reduction with ivabradine prevents thyroid hormone-induced cardiac remodeling in rat.
Topics: Animals; Anti-Arrhythmia Agents; Benzazepines; Calcium Signaling; Disease Models, Animal; Fibrosis; Heart Rate; Heart Ventricles; Hyperthyroidism; Ivabradine; Male; Myocardial Contraction; Myocytes, Cardiac; Rats; Rats, Sprague-Dawley; Stroke Volume; Thyroxine; Ultrasonography; Ventricular Dysfunction, Left; Ventricular Function, Left; Ventricular Remodeling | 2013 |
Rationale and design of a randomized, double-blind, placebo-controlled trial of ivabradine in patients with stable coronary artery disease and left ventricular systolic dysfunction: the morBidity-mortality EvAlUaTion of the I(f) inhibitor ivabradine in pa
Topics: Adult; Benzazepines; Cardiovascular Agents; Coronary Artery Disease; Double-Blind Method; Female; Heart Rate; Hospitalization; Humans; Ivabradine; Male; Middle Aged; Multicenter Studies as Topic; Myocardial Infarction; Randomized Controlled Trials as Topic; Research Design; Ventricular Dysfunction, Left | 2006 |
Heart failure management. Interview with Karl Swedberg.
Topics: Adrenergic beta-Antagonists; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Atrial Fibrillation; Benzazepines; Benzimidazoles; Biphenyl Compounds; Cardiac Output, Low; Chronic Disease; Defibrillators, Implantable; Humans; Ivabradine; Practice Guidelines as Topic; Tetrazoles; Ventricular Dysfunction, Left | 2007 |